Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome
- 28 June 2008
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 28 (2), 239-249
- https://doi.org/10.1111/j.1365-2036.2008.03730.x
Abstract
In models of irritable bowel syndrome (IBS), asimadoline, a kappa-opioid agonist, improves pain and abnormal bowel function. To evaluate the effects of three doses of asimadoline and placebo in subjects with IBS through a double-blind, randomized, placebo-controlled trial. Patients were randomly assigned to receive asimadoline 0.15, 0.5, 1.0 mg or placebo BID for 12 weeks. The primary efficacy measure was number of months of adequate relief of IBS pain or discomfort, with a prospective plan to evaluate adequate relief data by entry baseline pain and subtype. Several other endpoints were also evaluated. Five hundred and ninety-six patients were randomized. In the ITT population, statistically significant improvement on the primary endpoint was not seen. However, in diarrhoea-predominant IBS patients with at least baseline moderate pain, asimadoline (0.5 mg) produced significant improvement on total number of months with adequate relief of IBS pain or discomfort (46.7% vs. 20.0%), adequate relief of IBS symptoms (46.7% vs. 23.0%), pain scores (week 12: -1.6 vs. -0.7), pain free days (42.9% vs. 18.0%), urgency and stool frequency (-2.3 vs. -0.3). In patients with alternating IBS, significant improvement was seen on adequate relief endpoints. Asimadoline was well tolerated. Asimadoline warrants further evaluation as a treatment for IBS.Keywords
This publication has 18 references indexed in Scilit:
- Primary Endpoints for Irritable Bowel Syndrome Trials: A Review of Performance of EndpointsClinical Gastroenterology and Hepatology, 2007
- Personal view: adequate relief as a primary endpoint in irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2006
- Effect of asimadoline, a κ opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2004
- AGA technical review on irritable bowel syndromeGastroenterology, 2002
- Pharmacology and clinical experience with fedotozineExpert Opinion on Investigational Drugs, 2001
- Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5‐HT3 receptor antagonistAlimentary Pharmacology & Therapeutics, 1999
- Review article: irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 1997
- A pharmacological profile of the novel, peripherally-selective k-opioid receptor agonist, EMD 61753British Journal of Pharmacology, 1994
- K‐Opioid activity of the four stereoisomers of the peripherally selective κ‐agonists, EMD 60 400 and emd 61 753Chirality, 1994
- The Irritable Bowel Syndrome: Review and a Graduated Multicomponent Treatment ApproachAnnals of Internal Medicine, 1992